FK949E

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Major Depressive Disorder Patients

Conditions

Major Depressive Disorder Patients

Trial Timeline

May 1, 2009 → Mar 1, 2010

NCT ID

NCT01871974

About FK949E

FK949E is a phase 1 stage product being developed by Astellas Pharma for Major Depressive Disorder Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT01871974. Target conditions include Major Depressive Disorder Patients.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder Patients were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02362412	Phase 3	Completed	Feb 18, 2015	Feb 6, 2016	Bipolar Depression
NCT01737268	Phase 3	Completed	Oct 29, 2012	Jun 29, 2016	Bipolar Disorder
NCT01919008	Phase 1	Completed	Mar 26, 2012	Jun 22, 2012	Major Depressive Disorder
NCT01924520	Phase 1	Completed	Nov 1, 2010	May 1, 2011	Major Depressive Disorder
NCT01903200	Phase 1	Completed	Feb 1, 2010	Sep 1, 2011	Major Depressive Disorder Patients
NCT01871987	Phase 1	Completed	Jun 1, 2009	Aug 1, 2009	Healthy
NCT01871974	Phase 1	Completed	May 1, 2009	Mar 1, 2010	Major Depressive Disorder Patients

Competing Products

20 competing products in Major Depressive Disorder Patients

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	29
LY2216684 + SSRI	Eli Lilly	Phase 3	40
Duloxetine	Eli Lilly	Approved	43